Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to assess the response rate of the investigational drug
BMS-247550 (Ixabepilone) in women with metastatic breast cancer who are refractory to an
anthracycline, a taxane, and capecitabine.